报告摘要
Proteomics is the study of functions, structures, and interactions of the entire set of proteins that plays fundamental roles to shape and regulate the life. With great passion to reveal disease network, we have devoted efforts to develop mass spectrometry-based proteomic technologies for in-depth exploration of the proteome network and post-translational modification (PTM) in biology and diseases. In this talk, I will share our experiences and the long-term journey from the development of proteomics techniques to their utility in discovering new biology and opportunity for cancer diagnosis and precision medicine. Taking cancer research that requires multi-disciplinary efforts to cross the borders as an example, we also learn that team work will create higher impact in science. I will share the challenges and cross-border process how we assembled a multi-organization and multi-disciplinary team to launch a Cancer Moonshot project in 2016. Starting from scratch, the joint and highly multi disciplinary efforts delineated molecular signatures of pathogenesis and progression in non smoking lung cancer. Most excitingly, proteomics-informed classification demonstrated differentiation of the diverse clinical trajectories of patients within early stages. Nevertheless, the translation of proteomic discovery fasces multiple challenges in both technical robustness and sensitivity, as well as large-scale validation and assay development. I will also share how these scientific findings inspire the development of precision medicine strategies and our efforts to translate research assay into clinical laboratory.
报告人简介
Prof. Yu-Ju Chen
Distinguished Research Fellow, Institute of Chemistry, Academia Sinica
Adjunct Professor, Department of Chemistry, National Taiwan University
President, The Chinese Chemical Society located in Taipei (CSLT)
Associate Editor, Analytical Chemistry, ACS (2020-present)
